Financial Performance - The company's operating revenue for the reporting period was ¥165,656,377.77, a decrease of 11.80% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥10,161,397.17, representing a decline of 143.27% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥16,845,663.42, a decrease of 190.18% compared to the previous year[3]. - Basic earnings per share fell to -¥0.12, down 135.29% year-on-year[3]. Assets and Equity - Total assets at the end of the reporting period were ¥486,022,691.22, an increase of 10.13% from the beginning of the period[4]. - Shareholders' equity attributable to the company decreased by 1.87% to ¥290,601,818.15[4]. Operational Changes - The company expanded its management, research and development, and sales teams, leading to increased management, sales, and R&D expenses[7]. - The decline in revenue was primarily due to reduced high-margin product sales to overseas clients, particularly Philips, which implemented cost control measures[6]. - The company introduced a new 1.5T magnetic resonance imaging system as part of its strategic adjustments[7]. Non-Recurring Gains - Non-recurring gains included government subsidies of ¥8,442,902.52 and investment income of ¥509,016.85[4].
辰光医疗(430300) - 2023 Q4 - 年度业绩